title: Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
abstract: OBJECTIVE
  It may be useful to reduce the exposure of transplant recipients to homologous blood. This may be achieved by procuring donor-derived red blood cell (RBC) units, collecting more peripheral blood progenitor cells (PBPC) with a combination of granulocyte colony-stimulating factor (G-CSF) + recombinant human erythropoietin (rHuEpo) and by administering rHuEpo post-transplantation.
  
  
  METHODS
  Eight ABO-compatible donors were treated with rHuEpo and intravenous iron to collect 12 RBC units for use in their recipients. PBPC were collected after mobilization with rHuEpo and G-CSF in the same donors. The recipients received G-CSF and rHuEpo post-transplantation. A control group of 10 donor/recipient pairs received G-CSF alone for PBPC mobilization and after the transplantation.
  
  
  RESULTS
  Eighty-six out of 91 planned RBC units were collected in the donors without significant decrease in hematocrit because of a 4-fold increase in RBC production despite functional iron deficiency. After 2 leukaphereses, the cumulative yields of NC and CFU-GM were lower in the study group while those of BFU-E, CFU-Mix and CD34+ cells were similar. However, erythroid recovery was significantly accelerated in the study group.
  
  
  CONCLUSIONS
  Collection of 12 RBC units within 6 weeks is feasible with rHuEpo and intravenous iron; this strategy allows a dramatic reduction in recipient exposure to homologous blood; rHuEpo has no synergistic effect with G-CSF for mobilization of PBPC in normal donors and may even be deleterious; and rHuEpo in the recipient may enhance erythroid engraftment.
authors.affiliation: Department of Medicine, Division of Haematology, University of Liège, Liège, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Sautois
authors.forename: E
authors.initials: E
authors.lastname: Baudoux
authors.forename: J P
authors.initials: JP
authors.lastname: Salmon
authors.forename: S
authors.initials: S
authors.lastname: Michaux
authors.forename: N
authors.initials: N
authors.lastname: Schaaf-Lafontaine
authors.forename: M
authors.initials: M
authors.lastname: Pereira
authors.forename: J M
authors.initials: JM
authors.lastname: Paulus
authors.forename: G
authors.initials: G
authors.lastname: Fillet
authors.forename: Y
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D016238:Cytapheresis / Q000379:methods*; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000008:administration & dosage*; D005240:Feasibility Studies; D005260:Female; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D014184:Transplantation, Homologous
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor